mog peptide eae peptides - mog-peptide-35-55 peptide Understanding the MOG Peptide EAE Model: A Key Tool in Neurological Research

mod-peptide The MOG peptide EAE model stands as a cornerstone in the investigation of demyelinating diseases, particularly multiple sclerosis (MS). Experimental Autoimmune Encephalomyelitis (EAE), induced by specific myelin oligodendrocyte glycoprotein (MOG) peptides, offers researchers a robust animal model to unravel the complex immunopathology of central nervous system (CNS) autoimmune disorders. This article delves into the intricacies of the MOG peptide EAE model, exploring its induction, significance, and the valuable insights it provides into autoimmune-mediated myelin degradation.

The MOG Peptide: A Trigger for Autoimmunity

The MOG peptide is a crucial component in inducing EAE. Specifically, the MOG(35-55) peptide is widely recognized and utilized for its ability to reliably elicit an autoimmune response in susceptible animal strains, most commonly mice and rats. This specific peptide fragment, derived from the myelin oligodendrocyte glycoprotein, acts as an antigen that triggers an immune attack against the myelin sheath in the CNS.作者：A Dagkonaki·2020·被引用次数：28—...MOG-specific CD4+T cells. The results show that OM-MOGtreatsMOG-EAEin apeptide-specific manner, across mouse/human MHC class II ... Researchers often employ this MOG(35-55) peptide in conjunction with strong adjuvants, such as Complete Freund's Adjuvant (CFA), to enhance its immunogenic potential and ensure consistent EAE induction. The precise amount of MOG peptide used for immunization, typically around 100-200 $\mu$g, along with the chosen adjuvant, plays a critical role in the incidence and severity of the induced EAE.

Inducing Experimental Autoimmune Encephalomyelitis (EAE)

The induction of EAE in laboratory animals, such as C57BL/6 mice or Lewis rats, involves the subcutaneous injection of the MOG peptide emulsified in an adjuvant.Download scientific diagram | COAM reducesMOG peptide-inducedEAE. IFN-γ KO BALB/c mice were immunized with MOG35-55 and the test group was given 2 mg ... This process mimics the initiation of an autoimmune response.MOG (35-55) acetate (Synonyms: Myelin Oligodendrocyte ... Following immunization, a latency period occurs during which the immune system becomes sensitized to the MOG peptide.In practice, three primary myelin proteins, or characteristicpeptidescontained in these proteins, are used within Freund's adjuvant to induceEAE, including ... Subsequently, clinical signs of EAE emerge, characterized by paralysis and other neurological deficits, reflecting the demyelination and inflammation occurring in the CNS. The severity and phenotype of EAE can vary depending on the genetic background of the animal model, the specific MOG peptide sequence used (e.g., MOG 1-128 protein versus MOG(35-55) peptide), and the adjuvants employed. For instance, the MOG35-55 peptide-induced EAE model is particularly responsive to T cell modulating drugs, while other variants might exhibit different therapeutic responses.

Significance in Multiple Sclerosis Research

The MOG peptide EAE model is indispensable for studying the mechanisms underlying multiple sclerosis. MS is a chronic inflammatory disease of the CNS characterized by the immune system attacking the myelin sheath, leading to neurological dysfunction. By replicating key aspects of MS pathology, the MOG peptide-induced EAE model allows scientists to:

* Investigate Immunopathological Mechanisms: Researchers can meticulously study the roles of various immune cells, such as CD4+ T cells and CD8+ T cells, and their interactions in the autoimmune cascade leading to demyelination.MOG(35-55) (Myelin Oligodendrocyte GlycoproteinPeptide(35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling. The development of MOG-specific CD4+ T cells is a hallmark of this model.

* Develop and Test Therapeutics: The model serves as a crucial platform for preclinical testing of novel therapeutic strategies aimed at preventing, treating, or remyelinating damaged neural tissue. Studies involving Mannan-MOG35-55 have shown promise in treating MOG-EAE in a peptide-specific manner.

* Identify Biomarkers: By analyzing immune responses and disease progression in the EAE model, researchers can identify potential biomarkers for MS diagnosis and prognosis.

* Explore Genetic Susceptibility: Variations in EAE susceptibility and phenotype across different mouse strains highlight the genetic factors that may influence MS risk in humans.

Beyond MOG(35-55): Other MOG Peptides and Epitopes

While the MOG(35-55) peptide is the most common, other MOG peptides and fragments have also been investigated for their encephalitogenic potentialMOG(35-55) (Myelin Oligodendrocyte GlycoproteinPeptide(35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling.. For example, the MOG(1-125) and MOG(1-128) protein fragments have been used to induce EAE in different mouse strains. Furthermore, research has identified specific T cell epitopes within the MOG protein, such as peptide 119-128 and peptide 91-110, which are potent inducers of EAE and have been explored for therapeutic interventions. Understanding these different MOG peptides and their associated epitopes is vital for a comprehensive understanding of MOG-driven autoimmunity.

In conclusion, the MOG peptide EAE model, particularly utilizing the MOG(35-55) peptide, is an invaluable tool in neuroimmunology.MOG(35-55)-inducedEAEmodels can help elucidating the immunopathological mechanism of Multiple sclerosis and promote the developement of novel therapeutics. Its ability to recapitulate key features of demyelinating diseases like MS provides a critical platform for advancing our knowledge of disease pathogenesis and for the development of much-needed therapies. The ongoing research utilizing this model continues to shed light on the intricate interplay between the immune system and the CNS, paving the way for improved treatments for patients affected by these debilitating neurological conditions.